This Big Pharma stock is one of the safest bets, according to the Mad Money host, and it plays an attractive dividend to ...

Eli Lilly's drug, called eloralintide, helped some patients lose more than 11% of their body weight in three months.

AbbVie Inc. agreed to pay as much as $2.2 billion in March for an amylin drug from Danish biotech Gubra A/S, marking its first foray into the obesity market.

Drug developers are re-advancing amylin analogues for obesity, ... and AbbVie committed up to $2.3 billion to partner with Gubra on the phase I contender GUB014295. ...

Introduction & Market Context. Gubra AS (NASDAQ COPENHAGEN:GUBRA) presented its first quarter 2025 results on May 9, highlighting a transformative partnership with AbbVie (NYSE: ABBV) and progress in ...

Gubra’s first quarter was defined by the landmark exclusive global license agreement with AbbVie for GUBamy, a long-acting amylin analogue for obesity treatment.

The ballooning obesity drug market may have a new contender after Roche struck a $5.3 billion deal to develop Danish biotech Zealand Pharma’s “next generation” weight loss drug.